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Abstract
Background: The SF-36 has been used in a number of previous studies that have investigated the health status of
childhood cancer survivors, but it never has been evaluated regarding data quality, scaling assumptions, and reliability in
this population. As health status among childhood cancer survivors is being increasingly investigated, it is important that
the measurement instruments are reliable, validated and appropriate for use in this population. The aim of this paper was
to determine whether the SF-36 questionnaire is a valid and reliable instrument in assessing self-perceived health status
of adult survivors of childhood cancer.
Methods: We examined the SF-36 to see how it performed with respect to (1) data completeness, (2) distribution of
the scale scores, (3) item-internal consistency, (4) item-discriminant validity, (5) internal consistency, and (6) scaling
assumptions. For this investigation we used SF-36 data from a population-based study of 10,189 adult survivors of
childhood cancer.
Results: Overall, missing values ranged per item from 0.5 to 2.9 percent. Ceiling effects were found to be highest in the
role limitation-physical (76.7%) and role limitation-emotional (76.5%) scales. All correlations between items and their
hypothesised scales exceeded the suggested standard of 0.40 for satisfactory item-consistency. Across all scales, the
Cronbach's alpha coefficient of reliability was found to be higher than the suggested value of 0.70.
Consistent across all cancer groups, the physical health related scale scores correlated strongly with the Physical
Component Summary (PCS) scale scores and weakly with the Mental Component Summary (MCS) scale scores. Also,
the mental health and role limitation-emotional scales correlated strongly with the MCS scale score and weakly with the
PCS scale score. Moderate to strong correlations with both summary scores were found for the general health
perception, energy/vitality, and social functioning scales.
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Conclusion: The findings presented in this paper provide support for the validity and reliability of the SF-36 when used
in long-term survivors of childhood cancer. These findings should encourage other researchers and health care
practitioners to use the SF-36 when assessing health status in this population, although it should be recognised that ceiling
effects can occur.
Background
Dramatic improvements in anti-cancer therapy over the
last few decades have resulted in a growing number of
long-term survivors of childhood cancer. Although child-
hood cancer has become an increasingly more curable dis-
ease, the effects of this disease and its treatment may have
profound long-term effects on the health of survivors.
Due to this potential for adverse late effects, the health sta-
tus of survivors of childhood cancer has been more stud-
ied over recent years. However, the number of studies
focussing on self-perceived health of survivors is fairly lim-
ited, so that more research in this area is warranted.
An instrument that is designed to measure self-perceived
health status is the SF-36 health survey questionnaire.
This questionnaire has been used in a number of previous
studies that have investigated the health status of child-
hood cancer survivors [1-7], but it never has been evalu-
ated regarding data quality, scaling assumptions, and
reliability in this population.
As health status among childhood cancer survivors is
being increasingly investigated, it is important that the
measurement instruments are reliable, validated and
appropriate for use in this population. Although the psy-
chometric criteria of the SF-36 have been demonstrated
previously in the general population and in other patient
groups, it is unknown whether these criteria are also appli-
cable to the group of survivors of childhood cancer and
should therefore be tested empirically [8,9].
The aim of this study was to assess the data quality, score
reliability, and scaling assumptions of the SF-36 question-
naire in more than 10,000 long-term survivors of child-
hood cancer. This evaluation was based on the largest




This study used data from the British Childhood Cancer
Survivor Study (BCCSS), which is a population-based
cohort study of survivors of childhood cancer who were
16 years or older at the time of recruitment. The cohort
included all individuals who had been diagnosed with
childhood cancer between 1940 and 1991, in Britain, and
who had survived for at least 5 years. From 2000 to 2005,
14,450 survivors were mailed a questionnaire ascertaining
issues related to adverse health outcomes. For those who
did not mail the questionnaire back to the Study Centre,
up to three postal reminders were sent in the following
weeks. If a questionnaire was ultimately not returned then
this was considered as an implicit refusal. The question-
naire contained the standard form of the SF-36 (version 1)
which was administered at the beginning of the full ques-
tionnaire, as recommended by its developers [10].
Data on cancer diagnosis were obtained from the
National Registry of Childhood Tumours. Written
informed consent was obtained from each participant,
and the study was approved by the Multi-Centre Research
Ethics Committee and each of the 212 Local Research Eth-
ics Committees.
SF-36
The SF-36 is a generic health questionnaire, which con-
tains 36 items that measure eight dimensions (scales) of
health status. The eight dimensions are: physical function-
ing (PF), role limitation-physical (RP), role limitation-
emotional (RE), social functioning (SF), mental health
(MH), energy and vitality (EV), bodily pain (BP), and gen-
eral health perception (GH). Scores on each scale range
from 0–100, with a score of 100 indicating the highest rat-
ing of health. In addition, a Mental Component Summary
scale (MCS) and a Physical Component Summary (PCS)
scale can be derived from these eight scales by factor anal-
ysis. Because of the large sample size no imputation algo-
rithms were used to obtain scores for missing values.
Method of analysis
To assess whether the SF-36 is an appropriate tool for
measuring health status among survivors of childhood
cancer we used the following recommended criteria
[11,12]: (1) data completeness, (2) distribution of the
scale scores, (3) item-internal consistency, (4) item-discri-
minant validity, (5) internal consistency reliability, and
(6) scaling assumptions of the PCS and MCS. These crite-
ria were evaluated for the whole group of survivors, for
survivors with specific types of cancer, for survivors of dif-
ferent age groups, for both male and female survivors, and
for survivors with different ages at diagnosis. These strati-
fications were done in order to take possible heterogeneity
due to these factors into account.
First, the number of completed items and the amount of
missing data in every item were determined in order toHealth and Quality of Life Outcomes 2006, 4:77 http://www.hqlo.com/content/4/1/77
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assess data quality. Second, the distribution of the scale scores
was evaluated by assessing the percentage of lowest
(floor) and highest (ceiling) scores on the different scales.
Third, item-internal consistency was evaluated by calculat-
ing the correlation of every item with its hypothesised
scale (corrected for overlap). A correlation of above 0.40
has been suggested as being supportive of item-internal
consistency [10]. Fourth, item-discriminant validity was
examined by comparing the correlation between an item
and its hypothesised scale versus the correlation of that
same item with a supposedly unrelated scale. This com-
parison was performed for every item and every scale. A
difference of more than two standard errors between the
values of the correlations was accepted as a statistically sig-
nificant difference. Scaling success rates were calculated as
the proportion of successful comparisons relative to the
total number of comparisons. A comparison was deemed
successful whenever an item correlated significantly
higher with its hypothesised scale than with another,
unrelated, scale [10]. Fifth, Chronbach's alpha coefficient
of reliability was used to evaluate the internal consistency of
the SF-36. A Cronbach's alpha coefficient of 0.70 or
greater was considered satisfactory [12]. Lastly, to evaluate
the scaling assumptions of the PCS and MCS, both the scale
scores were derived by means of confirmatory factor anal-
ysis and correlations of every SF-36 scale with the PCS and
MCS scales were calculated. In order to support the two-
factor structure of the PCS and MCS, the physical health
related scales (PF, RP, BP) should correlate strongly (r ≥
0.7) with the PCS and weakly (r ≤ 0.3) with the MCS. Sim-
ilarly, the mental health related scales (MH, RE) should
correlate strongly (r ≥ 0.7) with the MCS and weakly (r ≤
0.3) with the PCS. The EV and GHP scales should correlate
moderately to strongly (≥ 0.3) with both summary scales,
and the SF scale should correlate strongly (r ≥ 0.7) with
the MCS and moderately (0.3 < r < 0.7) with the PCS.
Results
Seventy percent (n = 10,189) of the survivors returned the
questionnaire and completed at least one item on the SF-
36. Eighty-eight percent (n = 8,934) of those survivors
completed all items on the questionnaire, so that all scales
could be calculated. Missing values ranged per item from
0.5 to 2.9 percent, with items on the role limitation-emo-
tional scale having the highest percentage of missing val-
ues (range: 2.6–2.9%). There was no increase in missing
value rates in items near the end of the questionnaire.
For the survivor group as a whole, individual SF-36 scales
could not be calculated for only a small percentage of sur-
vivors (range: 1.8–3.9%). However, this percentage was
slightly higher among survivors of CNS tumours (range:
3.3–6.5%). The percentage of missing values in each scale
did not depend on sex, age at questionnaire completion,
or age at diagnosis (results not shown).
Overall, floor effects were most pronounced in the role-
limitation physical and role-limitation emotional scales,
but were relatively small (4.2%, 9.9% respectively). Ceil-
ing effects were found to be highest in the role limitation-
physical (76.7%) and role limitation-emotional (76.5%)
scales. Ceiling effects decreased with increase in age at
questionnaire completion, particularly in the physical
health related scales (Table 1).
Table 2 shows the range of item-scale correlations for all
survivors and by cancer diagnosis, sex, age at question-
naire completion, and age at diagnosis. All correlations
between items and their hypothesised scales exceeded the
suggested standard of 0.40 for satisfactory item-consist-
ency. Overall, the correlations between items and scales
other than their hypothesised scale all were lower than
correlations between items and their hypothesised scale.
However, item 9d (How much time during the last month
have you felt calm and peaceful?) correlated slightly
higher with the energy/vitality scale than with its hypoth-
esised scale (MH) among the overall cohort of survivors,
survivors of Wilms' tumours, Hodgkin's disease, and non-
Hodgkin's lymphomas, females, survivors younger than
39, and those diagnosed before the age of three.
Also, among survivors of leukaemia, those younger than
19, and those diagnosed before the age of 7, item 6 (To
what extent have your physical or emotional problems
interfered with your normal social activities?) correlated
higher with the role-emotional scale than with its hypoth-
esised scale (SF). The number of scaling failures did not
exceed two in any group, giving a scaling success rate of at
least 99.3% indicating high item-discriminant validity.
Across all scales, the Cronbach's alpha coefficient of relia-
bility was found to be higher than the suggested value of
0.70, with values ranging from 0.73 to 0.96 across the dif-
ferent cancer groups (Table 3).
Overall, the derived PCS and MCS scales together
explained 70.9% of the total variance. Consistent across
all cancer groups, the physical health related scale scores
(PF, RP, and BP) correlated strongly with the PCS scale
scores and weakly with the MCS scale (Table 4). Also, MH
and RE correlated strongly with the MCS scale score and
weakly with the PCS scale score. Moderate to strong corre-
lations with both summary scores were found for the gen-
eral health perception, energy/vitality, and social
functioning scales. These findings were consistent with
correlations that have been obtained in previous studies
involving the general population in the US [13] and the
UK [14]. However, there was a small discrepancy between
survivors and UK norm population data in the correlation
between the RE and the PCS scale, this correlation being
slightly higher among childhood cancer survivors. Also,Health and Quality of Life Outcomes 2006, 4:77 http://www.hqlo.com/content/4/1/77
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among survivors of age 16 to 19, the BP scale showed a
correlation below 0.7 (r = 0.55) with the PCS scale and a
correlation above 0.3 with the MCS scale (r = 0.49). These
violations were not found or at least much less pro-
nounced among older survivors.
Discussion
The findings of the present study suggest that the SF-36
exhibits good validity and reliability when used in long-
term survivors of childhood cancer. Apart from ceiling
effects observed in some scales, most properties were sat-
isfactory with regards to conventional psychometric crite-
ria.
Eighty-eight percent of the 10,189 subjects completed all
items, which is identical to the 88% observed in the UK
general population [14,15]. The percentage of missing
values per item ranged between 0.5 to 2.9 percent, indicat-
ing that no particular item on the SF-36 had a substan-
tially higher completion rate than other items. Missing
values per item were roughly similar to those found in a
UK normative general population sample (range: 0.43–
1.91) [14,15].
Ceiling effects were found to be highest in the role limita-
tion-physical (79.0%) and role limitation-emotional
(77.3%) scales. The ceiling effect observed in these two
scales can be explained, at least partly, by the dichoto-
mous format (yes vs. no) of the items (4a-d, 5a-c) that
measure these concepts. Ceiling effects in the role limita-
tion-physical and role limitation-emotional scale scores
have been found in other populations [10], so that this
effect cannot not solely be attributed to the specific
responses in childhood cancer survivors. The limitations
of these dichotomous items have been recognised by their
developers and, in the newer version of the SF-36 (version
2), a 5-point Likert scale has been used, in stead of the
dichotomous scale. According to the developers, this
should reduce the ceiling and floor effects generally
Table 1: Percentage of survivors scoring highest score possible (ceiling).
PF RP BP GH EV SF RE MH
all survivors 49.9 76.7 52.3 9.9 3.5 58.9 76.5 3.7
Cancer Diagnosis
leukaemia 56.3 82.6 57.0 12.0 5.0 63.6 79.9 4.5
Hodgkin's disease 57.7 80.9 53.9 5.5 2.6 61.3 77.7 2.4
non-Hodgkin's 56.6 81.3 55.3 10.4 5.0 59.4 75.1 3.3
CNS 34.2 63.3 49.1 7.6 2.1 46.7 69.9 2.8
neuroblastoma 45.9 77.3 50.1 9.8 4.2 58.8 77.3 4.4
retinoblastoma 63.0 80.3 56.0 14.9 3.6 65.8 77.6 4.6
Wilms' tumour 55.4 81.8 52.4 9.4 2.8 63.8 79.4 3.8
bone tumour 18.1 61.9 27.2 6.7 2.1 50.1 74.5 4.1
soft tissue sarcoma 51.2 77.4 49.5 10.9 3.8 60.1 75.4 4.4
other 55.8 81.9 54.7 10.0 3.2 64.5 79.2 3.6
Sex
Males 53.1 77.5 56.0 11.0 5.0 62.4 77.7 5.1
Females 42.5 71.3 45.6 8.1 1.7 52.3 70.1 2.1
Age*
16–19 56.8 82.4 58.5 12.8 6.3 64.3 79.0 5.3
20–29 54.4 78.9 55.7 10.6 3.8 58.8 77.1 3.9
30–39 49.1 75.8 50.7 8.9 2.3 57.7 76.0 3.2
40–49 39.9 69.9 45.0 7.5 2.2 56.8 73.0 2.5
50+ 21.6 63.2 34.7 6.7 1.9 53.6 74.8 2.7
Age at diagnosis
0–3 51.4 76.6 53.5 12.0 4.2 60.0 75.5 4.3
4–7 50.2 75.8 53.2 9.5 3.6 58.6 74.3 4.2
8–11 44.2 72.2 49.4 7.7 2.6 53.5 73.0 2.9
12–16 41.8 70.8 46.6 7.1 2.3 54.9 71.5 2.4
*Age at questionnaire completion
PF: Physical Functioning; RP: Role-Limitation Physical; BP; Bodily Pain;
GH: General Health Perception; EV: Energy/Vitality; SF: Social Functioning;
RE: Role-Limitation Emotional: MH: Mental HealthHealth and Quality of Life Outcomes 2006, 4:77 http://www.hqlo.com/content/4/1/77
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observed within these items and, thereby, should improve
precision.
The ceiling effects observed in the PF, RP, BP, SF, and RE
scale scores may be a consequence of the relative youth of
the childhood cancer survivor cohort. A young population
generally has better health status than the general popula-
tion, consequently, it will tend to score higher on most
scales, resulting in more common ceiling effects. When
comparing these ceiling effects between cancer survivors
and a sample from the general population [10,14] with a
similar age distribution, comparable percentages of ceil-
ing effects were found (results not shown), indicating that
the ceiling effects we observed are not specifically related
to the population of childhood cancer survivors. The
observed ceiling effects in these scales may however be a
result of the lack of sensitivity of these scales in general.
However, in large studies (n > 100) these ceiling effects
should not cause large difficulties when testing whether
two groups differ statistically from each other with regard
to their mean score on a SF-36 scale. It has been shown
that, probably as a result of the Central Limit Theorem,
the use of parametric methods, such as a t-test, when com-
paring means are fairly robust against violations of non-
normality [16]. The question whether the use of a mean is
an appropriate measure in the presence of non-normality
however remains. It is therefore advisable, in addition to
reporting mean scores or mean differences, to report scale
scores and scale score differences at the median and outer
centiles such as for example the 25th and 75th [14,17]. This
will give the potential reader insight in the nature of the
actual spread of the scale scores.
Item-internal consistency was acceptable, as all item-scale
correlations exhibited a value that exceeded 0.40. Accord-
ing to our findings, there is substantial evidence of discri-
minant validity of the SF-36 scales in adult survivors of
childhood cancer. This implies that the SF-36 scales can
discriminate between the different concepts that should
be measured.
Table 2: Item-internal consistency reliability coefficients and scaling failures (indicated by one or more stars).
PF RP BP GH EV SF RE MH
all survivors 0.69–0.88 0.75–0.82 0.81 0.61–0.81 0.71–0.74 0.67 0.70–0.76 0.52–0.73*
Cancer diagnosis
leukaemia 0.64–0.84 0.74–0.80 0.82 0.63–0.80 0.69–0.71 0.59** 0.67–0.74 0.47–0.72
Hodgkin's disease 0.62–0.84 0.72–0.83 0.79 0.51–0.78 0.73–0.75 0.74 0.70–0.74 0.58–0.75*
non-Hodgkin's 0.640.84 0.73–0.83 0.81 0.61–0.81 0.75–0.77 0.67 0.69–0.75 0.53–0.73*
CNS 0.70–0.89 0.75–0.82 0.82 0.59–0.81 0.69–0.73 0.67 0.73–0.79 0.48–0.69
neuroblastoma 0.64–0.90 0.79–0.83 0.82 0.58–0.84 0.70–0.74 0.62 0.66–0.75 0.51–0.76
retinoblastoma 0.65–0.89 0.69–0.81 0.79 0.55–0.78 0.70–0.73 0.61 0.67–0.73 0.54–0.76
Wilms' tumour 0.63–0.84 0.72–0.81 0.80 0.61–0.82 0.70–0.75 0.68 0.69–0.77 0.54–0.75*
bone tumour 0.48–0.86 0.75–0.84 0.82 0.49–0.81 0.71–0.76 0.71 0.80–0.85 0.56–0.76
soft tissue sarcoma 0.56–0.86 0.70–0.80 0.80 0.56–0.82 0.73–0.77 0.70 0.68–0.78 0.58–0.80
other 0.62–0.84 0.78–0.84 0.79 0.59–0.82 0.72–0.76 0.69 0.68–0.74 0.54–0.73
Sex
Males 0.68–0.88 0.73–0.81 0.79 0.57–0.80 0.71–0.74 0.66 0.70–0.75 0.51–0.72
Females 0.68–0.88 0.76–0.83 0.83 0.58–0.82 0.70–0.73 0.67 0.71–0.77 0.51–0.73*
Age†
16–19 0.66–0.88 0.66–0.74 0.77 0.58–0.80 0.66–0.71 0.57** 0.69–0.65 0.48–0.70*
20–29 0.68–0.87 0.73–0.81 0.80 0.59–0.81 0.71–0.75 0.65 0.69–0.76 0.53–0.74*
30–39 0.68–0.87 0.76–0.84 0.83 0.56–0.81 0.72–0.75 0.69 0.72–0.77 0.53–0.74*
40–49 0.71–0.90 0.80–0.85 0.81 0.59–0.83 0.74–0.76 0.73 0.72–0.81 0.55–0.74
50+ 0.62–0.88 0.76–0.87 0.83 0.55–0.81 0.66–0.74 0.69 0.78–0.82 0.49–0.71
Age at diagnosis
0–3 0.69–0.88 0.74–0.82 0.80 0.58–0.81 0.71–0.72 0.64** 0.69–0.76 0.50–0.72*
4–7 0.68–0.88 0.72–0.80 0.82 0.57–0.80 0.69–0.75 0.63** 0.69–0.75 0.52–0.72
8–11 0.68–0.88 0.76–0.83 0.82 0.58–0.83 0.73–0.75 0.70 0.73–0.77 0.52–0.74
12–16 0.64–0.88 0.78–0.84 0.81 0.56–0.81 0.72–0.75 0.71 0.71–0.78 0.55–0.74
*Scaling failure:item 9d correlated higher with EV than with MH **Scaling failure: item 6 correlated higher with RE than with SF
†Age at questionnaire completion
PF: Physical Functioning; RP: Role-Limitation Physical; BP; Bodily Pain; GH: General Health Perception; EV: Energy/Vitality;
SF: Social Functioning; RE: Role-Limitation Emotional: MH: Mental HealthHealth and Quality of Life Outcomes 2006, 4:77 http://www.hqlo.com/content/4/1/77
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Cronbach's alpha exceeded 0.70 for all scales, indicating
high internal consistency. The reliability, therefore, is
high. However, the high alpha coefficients observed may
be partly due to the ceiling effects observed in some scales.
The PCS and MCS scales explained over 70% of the total
variance, which is somewhat higher than the 66% of vari-
ance explained by these scales in the UK normative data
[14,15]. Obtained correlations between the eight scales
and the PCS and MCS scales in our data largely were sim-
ilar to the correlations between these eight scales and the
PCS and MCS scales found in the UK normative data
[14,15]. Although survivors showed a slightly higher cor-
relation between the role-emotional scale and the PCS
than the general population, this might be attributed to
the fact that the prevalence of physical problems associ-
ated with role emotional problems is higher among child-
hood cancer survivors than in the general population. For
example, neurological problems are more common
among childhood cancer survivors, and may affect the
survivor both physically and mentally. The moderate cor-
relation of the bodily pain scale with both the PCS and
MCS scales among young survivors (16–19 years) suggests
that those survivors who experience bodily pain are likely
to be more mentally than physically affected by bodily
pain than survivors of older age. Nonetheless, the overall
findings support the scaling assumptions of the SF-36
scales in our data, indicating that a two-factor model can
be used in evaluating health status among long-term sur-
vivors of childhood cancer.
Because of the population-based design of our study, the
validity and reliability of the SF-36 was assessed in a rep-
resentative sample of all childhood cancer survivors in the
UK. Respondents were similar to non-respondents with
respect to age, sex, diagnosis of childhood cancer, and
cancer treatment (Reulen et al. Health status of adult sur-
vivors of childhood cancer: a large scale population-based
study from the British Childhood Cancer Survivor Study
(submitted)).
Table 3: Internal consistency reliability coefficients (Cronbach's alpha).
PF RP BP GH EV SF RE MH
all survivors 0.95 0.91 0.87 0.87 0.87 0.79 0.86 0.84
Cancer Diagnosis
leukaemia 0.94 0.90 0.87 0.87 0.86 0.73 0.84 0.82
Hodgkin's disease 0.93 0.90 0.84 0.84 0.88 0.85 0.85 0.86
non-Hodgkin's 0.94 0.90 0.86 0.87 0.89 0.80 0.84 0.85
CNS 0.96 0.91 0.88 0.88 0.86 0.78 0.88 0.92
neuroblastoma 0.95 0.91 0.88 0.87 0.87 0.76 0.83 0.85
retinoblastoma 0.95 0.89 0.85 0.85 0.87 0.75 0.84 0.86
Wilms' tumour 0.93 0.90 0.86 0.87 0.87 0.81 0.86 0.85
bone tumour 0.93 0.91 0.89 0.85 0.88 0.83 0.91 0.85
soft tissue sarcoma 0.94 0.89 0.86 0.87 0.88 0.82 0.86 0.86
other 0.94 0.92 0.84 0.87 0.88 0.81 0.83 0.85
Sex
Males 0.95 0.90 0.85 0.86 0.87 0.78 0.85 0.83
Females 0.95 0.91 0.88 0.88 0.87 0.79 0.86 0.84
Age*
16–19 0.95 0.86 0.82 0.85 0.85 0.72 0.82 0.81
20–29 0.95 0.90 0.85 0.87 0.87 0.78 0.85 0.84
30–39 0.95 0.91 0.88 0.87 0.88 0.81 0.86 0.85
40–49 0.96 0.93 0.88 0.88 0.88 0.82 0.88 0.84
50+ 0.95 0.93 0.89 0.87 0.86 0.80 0.90 0.82
Age at diagnosis
0–3 0.95 0.90 0.86 0.87 0.87 0.77 0.85 0.83
4–7 0.95 0.90 0.87 0.87 0.86 0.76 0.85 0.84
8–11 0.95 0.91 0.87 0.87 0.88 0.81 0.87 0.84
12–16 0.95 0.92 0.87 0.87 0.88 0.82 0.87 0.85
*Age at questionnaire completion
PF: Physical Functioning; RP: Role-Limitation Physical; BP; Bodily Pain;
GH: General Health Perception; EV: Energy/Vitality; SF: Social Functioning;
RE: Role-Limitation Emotional: MH: Mental HealthHealth and Quality of Life Outcomes 2006, 4:77 http://www.hqlo.com/content/4/1/77
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A limitation of this study was that only cross-sectional
data was available and we were therefore not able to assess
the responsiveness of the SF-36 over time. However, as
survivors within this study will be followed-up over time,
and probably will complete another SF-36 questionnaire,
we probably will have the opportunity to assess the
responsiveness in future analyses. Hence, the findings in
this paper are only applicable to the use of the SF-36 in
studies comparing childhood cancer survivors to other
comparison groups.
In conclusion, the findings presented in this paper pro-
vide support for the validity and reliability of the SF-36
when used in long-term survivors of childhood cancer.
These findings should encourage other researchers and
health care practitioners to use the SF-36 when assessing
health status in this population, bearing in mind, how-
ever, its susceptibility to ceiling effects. The ceiling effects
observed were however not specific to the group of child-
hood cancer survivors and may therefore indicate the lack
of sensitivity of some SF-36 scales in general.
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Table 4: Correlation between scale scores and PCS/MCS scale scores.
PCS MCS
PF RP BP GH EV SF RE MH PF RP BP GH EV SF RE MH
UK norms [14] 0.79 0.75 0.78 0.64 0.38 0.51 0.11 0.13 0.05 0.26 0.20 0.42 0.73 0.65 0.78 0.89
Cancer Diagnosis
all survivors 0.85 0.82 0.73 0.60 0.40 0.62 0.27 0.13 0.13 0.27 0.32 0.53 0.76 0.59 0.73 0.91
leukaemia 0.83 0.81 0.69 0.55 0.33 0.63 0.28 0.13 0.14 0.24 0.36 0.59 0.80 0.57 0.68 0.90
Hodgkin's disease 0.83 0.81 0.72 0.55 0.34 0.61 0.20 0.16 0.09 0.27 0.37 0.55 0.78 0.60 0.77 0.89
non-Hodgkin's 0.85 0.77 0.78 0.70 0.40 0.54 0.25 0.13 0.13 0.29 0.25 0.40 0.78 0.65 0.79 0.92
CNS 0.88 0.82 0.67 0.66 0.47 0.67 0.32 0.11 0.10 0.28 0.37 0.48 0.71 0.54 0.70 0.91
neuroblastoma 0.81 0.80 0.71 0.50 0.32 0.55 0.20 0.07 0.04 0.31 0.45 0.62 0.78 0.67 0.75 0.88
retinoblastoma 0.83 0.83 0.75 0.54 0.31 0.50 0.28 0.05 0.16 0.21 0.26 0.55 0.80 0.64 0.75 0.92
Wilms' tumour 0.85 0.81 0.77 0.67 0.42 0.58 0.24 0.18 0.15 0.30 0.30 0.40 0.75 0.66 0.78 0.90
bone tumour 0.82 0.84 0.85 0.54 0.39 0.60 0.25 0.11 0.23 0.22 0.24 0.54 0.77 0.61 0.77 0.92
soft tissue sarcoma 0.85 0.80 0.78 0.67 0.44 0.52 0.19 0.14 0.11 0.27 0.28 0.44 0.70 0.68 0.81 0.90
other 0.83 0.77 0.80 0.61 0.45 0.60 0.25 0.16 0.17 0.34 0.24 0.52 0.73 0.61 0.78 0.90
Sex
Males 0.86 0.81 0.71 0.56 0.35 0.61 0.27 0.11 0.12 0.28 0.35 0.57 0.77 0.59 0.71 0.91
Females 0.85 0.82 0.75 0.63 0.43 0.63 0.27 0.12 0.14 0.27 0.29 0.49 0.75 0.59 0.75 0.91
Age*
16–19 0.84 0.82 0.55 0.47 0.28 0.62 0.27 0.10 0.11 0.25 0.49 0.62 0.82 0.58 0.67 0.89
20–29 0.86 0.80 0.71 0.59 0.40 0.59 0.22 0.14 0.10 0.28 0.30 0.52 0.75 0.61 0.76 0.91
30–39 0.85 0.81 0.75 0.57 0.36 0.62 0.27 0.13 0.15 0.28 0.30 0.54 0.78 0.60 0.73 0.90
40–49 0.85 0.84 0.76 0.69 0.44 0.68 0.37 0.14 0.19 0.26 0.31 0.46 0.74 0.56 0.70 0.92
50+ 0.84 0.82 0.82 0.66 0.55 0.65 0.26 0.19 0.23 0.28 0.22 0.50 0.65 0.56 0.75 0.90
Age at diagnosis
0–3 0.85 0.82 0.71 0.59 0.36 0.62 0.31 0.11 0.11 0.28 0.36 0.53 0.79 0.59 0.71 0.91
4–7 0.86 0.82 0.69 0.60 0.41 0.65 0.24 0.13 0.11 0.24 0.35 0.53 0.74 0.57 0.74 0.90
8–11 0.87 0.80 0.75 0.59 0.40 0.58 0.27 0.12 0.13 0.31 0.30 0.53 0.75 0.61 0.74 0.91
12–16 0.84 0.82 0.79 0.59 0.40 0.61 0.24 0.13 0.18 0.26 0.26 0.54 0.76 0.61 0.76 0.91
*Age at questionnaire completion
PF: Physical Functioning; RP: Role-Limitation Physical; BP; Bodily Pain; GH: General Health Perception; EV: Energy/Vitality; SF: Social Functioning;
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